Loading
In chronic myeloid leukaemia, how far the leukaemia gene signal in the blood has fallen, measured in logs: a 1,000-fold drop is a major molecular response, a 10,000-fold drop (MR4) is 'deep'. Deep responses held for two years let some patients stop their pills.
Quantitative PCR for BCR::ABL1 transcripts on the International Scale defines milestones: ≤10% at 3 months (early molecular response), ≤1% (complete cytogenetic response equivalent), ≤0.1% (MMR) by 12 months, ≤0.01% (MR4) and ≤0.0032% (MR4.5). Missing milestones triggers a switch of TKI. Sustained deep response for at least two years permits a supervised stop; about half stay in treatment-free remission and the rest regain response on restarting (EURO-SKI). 'Molecular relapse' is a rising transcript before any clinical sign. The concept is being borrowed for ctDNA-guided stopping in solid tumours.
Showing the molecule this term concerns: Imatinib.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares Nilotinib, Asciminib, Chronic myeloid leukaemia, chronic phase, Dasatinib.
Shares BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR), BCR::ABL1 kinase domain mutations (T315I and others), Asciminib, Chronic myeloid leukaemia, chronic phase.
Shares Nilotinib, Asciminib, Chronic myeloid leukaemia, chronic phase, Dasatinib.
Shares BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR), BCR::ABL1 kinase domain mutations (T315I and others), Philadelphia chromosome (Ph+, BCR::ABL1), Nilotinib.
Shares Sokal and ELTS risk scores (chronic myeloid leukaemia), BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR), BCR::ABL1 kinase domain mutations (T315I and others), Chronic myeloid leukaemia, chronic phase.
Shares Nilotinib, Asciminib, Chronic myeloid leukaemia, chronic phase.
Shares Nilotinib, Asciminib, Chronic myeloid leukaemia, chronic phase, Dasatinib.
Shares BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR), BCR::ABL1 kinase domain mutations (T315I and others), Philadelphia chromosome (Ph+, BCR::ABL1), Asciminib.